Description References
ChemicalBook > CAS DataBase List > Pemetrexed Disodium

Pemetrexed Disodium

Description References
Product Name
Pemetrexed Disodium
CAS No.
150399-23-8
Chemical Name
Pemetrexed Disodium
Synonyms
ALIMTA;LY-231514;PEMETREXED SODIUM;Alimt;AliMta disodiuM;LY231514 disodiuM;LY 231514 disodiuM;LY-231514 disodiuM;PeMetexed DisodiuM;Pemwtrexed Disodium
CBNumber
CB4385473
Molecular Formula
C20H22N5NaO6
Formula Weight
451.41
MOL File
150399-23-8.mol
More
Less

Pemetrexed Disodium Property

Melting point:
254-258°C (dec.)
storage temp. 
Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
solubility 
Methanol, Water
form 
Solid
color 
Off-White
Stability:
Hygroscopic
InChI
InChI=1/C20H21N5O6.Na.H/c21-20-24-16-15(18(29)25-20)12(9-22-16)6-3-10-1-4-11(5-2-10)17(28)23-13(19(30)31)7-8-14(26)27;;/h1-2,4-5,9,13H,3,6-8H2,(H,23,28)(H,26,27)(H,30,31)(H4,21,22,24,25,29);;/t13-;;/s3
InChIKey
UTEALKYVANXUSG-NVZXTOETNA-N
SMILES
C(C1=CNC2NC(N)=NC(=O)C1=2)CC1C=CC(C(=O)N[C@H](C(=O)O)CCC(=O)O)=CC=1.[NaH] |&1:20,r|
CAS DataBase Reference
150399-23-8(CAS DataBase Reference)
More
Less

Safety

Hazard Codes 
T;Xi,Xi,T
Risk Statements 
36/38-60-61-68
Safety Statements 
36/37/39-53
More
Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)
Signal word
Warning
Hazard statements

H302Harmful if swallowed

H315Causes skin irritation

H319Causes serious eye irritation

H335May cause respiratory irritation

Precautionary statements

P261Avoid breathing dust/fume/gas/mist/vapours/spray.

P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

More
Less

N-Bromosuccinimide Price

ApexBio Technology
Product number
A4390
Product name
Pemetrexed
Packaging
1unit
Price
$28
Updated
2021/12/16
ApexBio Technology
Product number
A4390
Product name
Pemetrexed
Packaging
100mg
Price
$50
Updated
2021/12/16
ApexBio Technology
Product number
A4390
Product name
Pemetrexed
Packaging
10mM(in 1mL DMSO)
Price
$50
Updated
2021/12/16
Biosynth Carbosynth
Product number
BP164243
Product name
Pemetrexed disodium
Packaging
50mg
Price
$50
Updated
2021/12/16
ChemScene
Product number
CS-1298
Product name
Pemetrexed disodium
Purity
99.99%
Packaging
50mg
Price
$60
Updated
2021/12/16
More
Less

Pemetrexed Disodium Chemical Properties,Usage,Production

Description

Pemetrexed disodium (marketed as ALIMTA®, “pemetrexed”) is a novel, multi-targeted antifolate. It suppresses tumor growth by impeding both DNA synthesis and folate metabolism. Pemetrexed disodium has demonstrated promising clinical activity in a wide variety of solid tumors, including non-small cell lung, breast, mesothelioma, colorectal, pancreatic, gastric, bladder, cervix, and head and neck.
Pemetrexed disodium is approved to be used alone or with other drugs to treat malignant pleural mesothelioma in patients who cannot be treated with surgery and non-small cell lung cancer (certain types) in patients whose disease is locally advanced or has metastasized (spread to other parts of the body). Pemetrexed disodium is also being studied in the treatment of other types of cancer.

References

[1] https://www.cancer.gov/about-cancer/treatment/drugs/pemetrexeddisodium
[2] Axel-R. Hanauske, V. Chen P. Paoletti, C. Niyikiza (2001) Pemetrexed Disodium: A Novel Antifolate Clinically Active Against Multiple Solid Tumors, The Oncologist, 6, 363-373

Description

Pemetrexed, a pyrrolo[2,3-d]pyrimidine-based antifolate that disrupts cell replication by inhibiting multiple folate-dependent metabolic processes, was initially developed and launched in the US for the treatment of malignant pleural mesothelioma in conjunction with cisplatin. Patients who are not candidates for surgery may benefit from this combination therapy. Clinical data demonstrated that the median overall survival time increased to 12.1 months, compared with 9.3 months for patients receiving cisplatin alone. In August of 2004, the FDA also approved pemetrexed as a second-line treatment of non-small-cell lung cancer (NSCLC). While median survival is comparable to the standard second-line treatment docetaxel, the improved toxicity profile (significant reduction in neutropenia) accelerated the approval for NSCLC. Its effectiveness as an anticancer drug is derived from its ability to gain internal cell access via the reduced folate carrier and membrane folate binding protein transport systems. Once inside, pemetrexed undergoes polyglutamation, and the resultant polyglutamate forms (predominantly the pentaglutamate) inhibit the folate-dependent enzymes thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT). Against recombinant human TS, pemetrexed has a Ki of 109nM while the triglutamate and pentaglutamate forms have Ki values of 1.6nM and 1.3 nM, respectively. All forms of pemetrexed display similar potency against recombinant human DHFR (7 nM), but the pentaglutamate form is significantly more potent against recombinant murine GARFT than the parent (Ki=65nM versus 9.3μM). The selectivity of pemetrexed may be explained by the fact that polyglutamation is more likely to occur in cancer cells compared to normal cells while its prolonged duration of action may be attributed to decreased cellular efflux of the polyglutamate forms. While several different routes have provided pemetrexed, one of the most efficient exploits the propensity of 2,6-diamino-3Hpyrimidin- 4-one to undergo Michael additions at its unsubstituted C-5 position. Using ethyl 4-(4-nitrobut-3-enyl)benzoate as the Michael acceptor, the resulting adduct is then converted to the ultimate precursor for glutamyl coupling via a onepot, three-step process (Nef reaction to transform the nitro to the aldehyde, intramolecular condensation to afford the pyrrole, and saponification of the ethyl ester). A typical treatment regimen involves intravenous administration of pemetrexed, infused over ten minutes, at a dose of 500mg/m2 followed by a thirty minute wash-out period and then cisplatin intravenously over two hours at a dose of 75mg/m2. Both drugs are given on Day 1 of a 21-day cycle. In order to reduce treatment-related hematological and GI toxicity, patients are instructed to take folic acid and vitamin B12 as a prophylactic measure. Pretreatment with a corticosteroid is also recommended to prevent possible skin rashes. Pemetrexed is primarily excreted intact in the urine, with 70–90% of the dose being recovered within 24 hours of administration. The half-life of pemetrexed is 3.5 hours in patients with normal renal function, and the total systemic clearance is 91.8mL/min. As expected, clearance decreases as renal impairment increases. The drug’s plasma protein binding is 81%, and it has a steady state volume of distribution of 16.1 L. The pharmacokinetics of pemetrexed is linear with dose and remains unchanged over multiple treatment cycles. While in vitro studies suggest that pemetrexed would not interfere with drugs metabolized by CYP3A4, CYP2D6, CYP2C9, and CYP1A2, ibuprofen (400mg q.d.) does reduce pemetrexed clearance by 20%. Caution should, therefore, be taken when administering pemetrexed concurrently with ibuprofen to patients with renal insufficiency and should not be given at all to patients whose creatinine clearance is ＜45mL/min. .

Chemical Properties

Crystalline Solid

Originator

Eli Lilly (US)

Uses

Multitargeted antifolate; inhibits thymidylate synthase as well as other folate dependent enzymes. Antineoplastic.

Uses

Pemetrexed is a novel antifolate and antimetabolite for TS, DHFR and GARFT with Ki of 1.3 nM, 7.2 nM and 65 nM, respectively

Definition

ChEBI: An organic sodium salt that is the disodium salt of N-{4-[2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-L-glutamic acid. Inhibits thymidylate synthase (TS), 4 1 dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT).

brand name

Alimta (Lilly).

General Description

The drug is available in a 100-mg sterile vial for IV use. Thedrug appears to be effective against a range of tumors includingmesothelioma, NSCLC, colorectal cancer, bladdercancer, and lung cancer. The mechanism of action involvesinhibition of TS resulting in inhibition of thymidylate andDNA synthesis. This drug is a pyrrolopyrimidine analog offolate with antifolate activity. Resistance can occur by increasedexpression of TS, decreased binding affinity for TS,or decreased drug transport into cells. The drug is administeredonly via the IV route and distributes to all tissues.Cellular activation to the more potent polyglutamated formsoccurs, and the majority of the dose is excreted unchangedin the urine. The drug interaction and toxicity profiles aresimilar to that of methotrexate.

Mechanism of action

Like methotrexate, it is actively transported into tumor cells through reduced folate carriers and, in polyglutamated form, inhibits the synthesis of pyrimidine and purine-based nucletotides by disrupting folatedependent metabolic processes . In addition to DHFR, this pyrrolopyrimidine-based inhibitor binds tightly to thymidylate synthase and GAR transformylase.

Clinical Use

Pemetrexed is a novel multitarget antifolate used by the IV route for the treatment of advanced or metastatic nonsmall cell lung cancer and in combination with cisplatin in malignant pleural mesothelioma.

Side effects

Patients on pemetrexed must take folate and vitamin B12 supplements to reduce the risk of bone marrow suppression (neutropenia, thrombocytopenia, and anemia) and GI side effects. Pretreatment with corticosteroids can reduce the risk of drug-induced skin rash. Pemetrexed has a half-life of 3.5 hours and is excreted primarily unchanged via the kidneys. Significant cross-resistance has been noted between pemetrexed and other pyrimidine and folate antagonists.

Synthesis

A number of papers outlining the syntheses of pemetrexed and related analogs have appeared. A practical and scalable synthetic route is depicted in Scheme 9. Palladium (0) coupling of methyl 4-bromobenzoate (57) with 3-butyn-1-ol (58) gave crystalline 59, which was then reduced over palladium on carbon in DCM to give alcohol 60. Filtration of the catalyst afforded a DCM solution of alcohol 60, which was utilized directly in a TEMPO-catalyzed sodium hypochlorite oxidation, providing known aldehyde 61 without isolation. Addition of 5,5-dibromobarbituric acid (DBBA) and catalytic amount of HBr in acetic acid to the DCM solution of 61 effected the conversion to a-bromoaldehyde 62. After aqueous work-up, the solution was concentrated and diluted with acetonitrile to exchange solvents. Addition of commercially available 2,4-diamino-6-hydroxypyrimidine (63), aqueous sodium acetate and heating to 45??C resulted in cyclic condensation and precipitation of pyrrolo[2,3- d]pyrimidine 64 from the reaction mixture in 67% yield based on 60. Saponification of 64 with aqueous sodium hydroxide followed by acidification afforded the carboxylic acid derivative 65, which was elaborated to 66 by chlorodimethoxytriazine active ester coupling method. Reaction of 65 with 2-chloro-4,6-dimethoxy-1,3,5-triazine (CDMT) in the presence of N-methylmorpholine in DMF solution followed by reaction of the resulting dimethoxy-s-triazinyl ester with diethyl L-glutamate afforded crude 66, which was isolated via crystallization as pTSA salt 67. Saponification of 67 with aqueous sodium hydroxide followed by acidification with HCl gave pemetrexed as the free acid, which was crystallized as disodium salt form.

target

MEK | ERK

Drug interactions

Potentially hazardous interactions with other drugs
Antimalarials: antifolate effect increased by pyrimethamine.
Antipsychotics: avoid with clozapine, increased risk of agranulocytosis.
Nephrotoxic agents: may reduce clearance of pemetrexed - use with caution.
Live vaccines: avoid use; YELLOW FEVER VACCINE ABSOLUTELY CONTRAINDICATED.

Metabolism

Pemetrexed undergoes minimal hepatic metabolism, and about 70-90% of a dose is eliminated unchanged in the urine within 24 hours. In vitro studies indicate that pemetrexed is actively secreted by OAT3 (organic anion transporter).

Pemetrexed Disodium Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Pemetrexed Disodium Suppliers

Canada 1 China 419 Europe 2 Germany 1 India 21 South Korea 1 United Kingdom 8 United States 45 Global 498
Pure Chemistry Scientific Inc.
Tel
001-857-928-2050 or 1-888-588-9418
Fax
001-617-206-9595
Email
sales@chemreagents.com
Country
United States
ProdList
10186
Advantage
62
LGM Pharma
Tel
1-(800)-881-8210
Fax
615-250-9817
Email
inquiries@lgmpharma.com
Country
United States
ProdList
2123
Advantage
70
AdooQ BioScience, LLC
Tel
+1 (866) 930-6790
Fax
+1 (866) 333-9607
Email
info@adooq.com
Country
United States
ProdList
2782
Advantage
58
HBCChem, Inc.
Tel
+1-510-219-6317
Fax
+1-650-486-1361
Email
sales@hbcchem.com
Country
United States
ProdList
10648
Advantage
60
EMMX Biotechnology LLC
Tel
888-539-0666
Fax
888-539-0666
Email
info@emmx.com
Country
United States
ProdList
8447
Advantage
60
Target molecule Corp.
Tel
857-239-0968
Fax
857-239-8801
Email
service1@targetmol.com
Country
United States
ProdList
2559
Advantage
60
Alfa Chemistry
Tel
+1-5166625404;
Fax
1-516-927-0118
Email
Info@alfa-chemistry.com
Country
United States
ProdList
20405
Advantage
58
TargetMol Chemicals Inc.
Tel
+1-781-999-5354; +17819995354
Email
marketing@targetmol.com
Country
United States
ProdList
32435
Advantage
58
InvivoChem
Tel
+1-708-310-1919 +1-13798911105
Fax
708-557-7486
Email
sales@invivochem.cn
Country
United States
ProdList
6391
Advantage
58
BOC Sciences
Tel
+1-631-485-4226
Fax
1-631-614-7828
Email
inquiry@bocsci.com
Country
United States
ProdList
19552
Advantage
58
Cato Research Chemicals Inc.
Tel
+86-020-81960175-877 4000-868-328
Email
tianwen.zhan@cato-chem.com
Country
United States
ProdList
10404
Advantage
58
TargetMol Chemicals Inc.
Tel
+17819995354
Email
marketing@targetmol.com
Country
United States
ProdList
19962
Advantage
58
TargetMol Chemicals Inc.
Tel
+1-781-999-5354;
Email
support@targetmol.com
Country
United States
ProdList
39035
Advantage
58
Aladdin Scientific
Tel
Email
tp@aladdinsci.com
Country
United States
ProdList
57505
Advantage
58
Protheragen-ING
Tel
+16313385890
Email
info@protheragen-ing.com
Country
United States
ProdList
3868
Advantage
58
ApexBio Technology
Tel
--
Fax
--
Email
sales@apexbt.com
Country
United States
ProdList
6251
Advantage
58
CarboMer, Inc.
Tel
--
Fax
--
Email
sales@carbomer.com
Country
United States
ProdList
4026
Advantage
67
LC Laboratories
Tel
--
Fax
--
Email
custserv@lclabs.com
Country
United States
ProdList
503
Advantage
50
CHEMWERTH INC
Tel
--
Fax
--
Email
sales@chemwerth.com
Country
United States
ProdList
56
Advantage
58
United States Biological
Tel
--
Fax
--
Email
chemicals@usbio.net
Country
United States
ProdList
6214
Advantage
80
Creative Enzymes
Tel
--
Fax
--
Email
info@creative-enzymes.com
Country
United States
ProdList
6057
Advantage
58
MedChemExpress
Tel
--
Fax
--
Email
sales@medchemexpress.com
Country
United States
ProdList
6398
Advantage
58
Combi-Blocks Inc.
Tel
--
Fax
--
Email
sales@combi-blocks.com
Country
United States
ProdList
6618
Advantage
69
Matrix Scientific
Tel
--
Fax
--
Email
sales@matrixscientific.com
Country
United States
ProdList
6632
Advantage
80
Selleck Chemicals LLC
Tel
--
Fax
--
Email
info@selleckchem.com
Country
United States
ProdList
824
Advantage
60
Tractus USA LLC
Tel
--
Fax
--
Country
United States
ProdList
227
Advantage
60
Focus Synthesis LLC
Tel
--
Fax
--
Email
acd@focussynthesis.com
Country
United States
ProdList
2487
Advantage
61
ChemieTek
Tel
--
Fax
--
Email
info@chemietek.com
Country
United States
ProdList
219
Advantage
50
Santa Cruz Biotechnology, Inc.
Tel
--
Fax
--
Email
scbt@scbt.com
Country
United States
ProdList
3597
Advantage
60
Fragmenta
Tel
--
Fax
--
Email
sales@fragmenta.com
Country
United States
ProdList
1068
Advantage
0
Tecoland Corporation
Tel
--
Fax
--
Email
info@tecoland.com
Country
United States
ProdList
275
Advantage
50
Ivy Fine Chemicals
Tel
--
Fax
--
Email
sales@ivychem.com
Country
United States
ProdList
6493
Advantage
58
AlliChem, LLC
Tel
--
Fax
--
Email
sales@allichemllc.com
Country
United States
ProdList
6516
Advantage
60
Medical Isotopes
Tel
--
Fax
--
Email
stohler@medicalisotopes.com
Country
United States
ProdList
6181
Advantage
68
Waterstone Technology, LLC
Tel
--
Fax
--
Email
sales@waterstonetech.com
Country
United States
ProdList
6786
Advantage
30
2A PharmaChem USA
Tel
--
Fax
--
Email
sales@2apharmachem.com
Country
United States
ProdList
6137
Advantage
39
3B Scientific Corporation
Tel
--
Fax
--
Email
sales@3bsc.com
Country
United States
ProdList
6718
Advantage
47
HONEST JOY HOLDINGS LIMITED
Tel
--
Fax
--
Email
sales@honestjoy.cn
Country
United States
ProdList
6675
Advantage
54
APAC Pharmaceutical, LLC
Tel
--
Fax
--
Email
sales@apacpharma.com
Country
United States
ProdList
6322
Advantage
38
Beta Pharma, Inc.
Tel
--
Fax
--
Email
sales@betapharma.com
Country
United States
ProdList
6226
Advantage
60
AK Scientific, Inc.
Tel
--
Fax
--
Email
sales@aksci.com
Country
United States
ProdList
6347
Advantage
65
QVENTAS INC.
Tel
--
Fax
--
Email
mike@qventas.com
Country
United States
ProdList
383
Advantage
47
BOSCHE SCIENTIFIC, LLC
Tel
--
Fax
--
Email
Sales@BoscheSci.com
Country
United States
ProdList
6477
Advantage
55
American Custom Chemicals Corporation
Tel
--
Fax
--
Email
sales@acccorporation.com
Country
United States
ProdList
6820
Advantage
51
ChemPacific Corporation
Tel
--
Fax
--
Email
sales@chempacific.com
Country
United States
ProdList
6891
Advantage
51
More
Less

View Lastest Price from Pemetrexed Disodium manufacturers

Wuhan JiyunZen Tech Co., Ltd.
Product
Pemetrexed Disodium 150399-23-8
Price
US $5.00-0.50/KG
Min. Order
1KG
Purity
99% hplc
Supply Ability
500TONS
Release date
2025-05-08
WUHAN FORTUNA CHEMICAL CO., LTD
Product
Pemetrexed disodium 150399-23-8
Price
US $0.00/g/Bag
Min. Order
1g
Purity
99%min
Supply Ability
10kg
Release date
2021-10-18
Zibo Hangyu Biotechnology Development Co., Ltd
Product
Pemetrexed Disodium 150399-23-8
Price
US $20.00-80.00/mg
Min. Order
50mg
Purity
99%
Supply Ability
50
Release date
2024-07-10

150399-23-8, Pemetrexed DisodiumRelated Search:

Ethyl acetate ISOXADIFEN-ETHYL 2-Ethoxyethanol Raltitrexed N-Methyl-2-pyrrolidone Ethylparaben Trinexapac-ethyl Ethanol Disodium succinate Polyvinylpyrrolidone 4-Ethyl-5-fluoro-6-hydroxypyrimidine Ethylenediaminetetraacetic acid disodium salt Ethyl formate Pemetrexed disodium hemipentahydrate Pemetrexed Disodium Heptahydrate Sodium Monofluorophosphate 4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pymol[2,3-d]pyrimodin-5-yl)ethyl]benzoic acid Gemcitabine

  • n-[4-[2-(2-amino-4,7-dihydro-4-oxo-1h-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid disodium salt
  • PEMETREXED DISODIUM(ALIMTA)
  • PEMETREXED SODIUM
  • PEMETREXED DISODIUM 99%
  • PEMETREXED DISODIUM 2.5H2O
  • PEMETREXED DISODIUM FOR INJECTION
  • PEMETREXED DISODIUM FOR INJECTION BK-A-01
  • Pemetrexed Dinatrium
  • ALIMTA
  • Alimt
  • LY-231514
  • N-[4-[(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic Acid Disodium
  • Pemwtrexed Disodium
  • 2-[4-[2-(4-Amino-2-oxo-3,5,7-triazabicyclo[4.3.0]nona-3,8,10-trien-9-yl)ethyl]benzoyl]aminopentanedioic acid disodium salt
  • PeMetrexed disodiuM (LY-231514)
  • PEMETREXED DISODIUM 7 H2O
  • PeMetrexed (AliMta)
  • N-[4-[2-(2-AMino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyriMidin-5-yl)ethyl]benzoyl]-L-glutaMic Acid SodiuM Salt
  • AliMta disodiuM
  • LY 231514 disodiuM
  • LY231514 disodiuM
  • LY-231514 disodiuM
  • PeMetexed DisodiuM
  • Pemetrexed Disodium Salt
  • disodiuM (2S)-2-{[4-(2-{2-aMino-4-oxo-3H,4H,7H-pyrrolo[2,3-d]pyriMidin-5-yl}ethyl)phenyl]forMaMido}pentanedioic acid
  • Sodium (S)-2-(4-(2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl)benzamido)
  • Two sodium for the United States and the United States
  • Pemetrexed phosphate
  • sodium (S)-2-(4-(2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl)benzamido)pentanedioate
  • N-[4-[2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid disodium salt Pemetrexed
  • Pemetrexed Disodium ，≥99%
  • Pemetrexed disodium, a novel antifolate
  • Pemetrexed disodium USP/EP/BP
  • Pemetrexed Disodium(USFDA)
  • Sodium (4-(2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl)benzoyl)-L-glutamate
  • Pemetrexed disodium
  • L-Glutamic acid, N-[4-[2-(2-amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-, sodium salt (1:2)
  • N-4-2-(2-Amino-4,7-dihydro-4-oxo-3H-pyrrolo2,3-dpyrimidin-5-yl)ethylbenzoyl-L-glutamic acid disodium salt
  • Pemetrexed disodium, 10 mM in DMSO
  • PEMETREXED DISODIUM USP
  • Pemetrexed disodium salt - Bio-X ?
  • Pemetrexed disodium (LY231514 disodium
  • 150399-23-8
  • 357166-90-4
  • 150339-23-8
  • C20H21N5O62Na
  • C20H19N5Na2O6
  • C20H33N5Na2O13
  • C20H19N5O62Na
  • LY-231514
  • Molecular Targeted Antineoplastic
  • All Inhibitors
  • Inhibitors
  • Intermediates & Fine Chemicals
  • Pharmaceuticals
  • Chiral Reagents